ARPA-H is calling on researchers, clinicians, and innovators across academia, industry, and government to accelerate early-stage Phase 1 and Phase 2 clinical trials of ibogaine as a treatment for opioid use disorder. No federally authorized clinical trials of ibogaine for OUD currently exist in the United States despite early anecdotal reports of reduced cravings and withdrawal symptoms, and the program aims to close that evidence gap with trials that prioritize patient safety and translation into Phase 3 testing. The effort aligns with Executive Order 14401 on accelerating medical treatments for serious mental illness.

Solution summaries are requested by October 15, 2026 at 9:00 p.m. ET. To review the notice, click on the link here.